GLP-1s, like Ozempic, Wegovy, & Mounjaro, can be expensive, but how does this impact the healthcare ecosystem? Or the GDP and national economics? And are they worth the cost?
In this video, part two of Omada’s video blog series, Chief Medical Officer Carolyn Bradner Jasik, MD covers the cost of GLP-1 medications and its potential impact on the healthcare system expenditure.
